½ÃÀ庸°í¼­
»óǰÄÚµå
1750649

µ­±â¿­ °Ë»ç ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® ¸®Æ÷Æ® : Á¦Ç° À¯Çüº°, ¼­ºñ½º À¯Çüº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2025-2030³â)

Dengue Testing Market Size, Share & Trends Analysis Report By Product, By Service Type, By End-use, By Region, And Segment Forecasts, 2025 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 195 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

µ­±â¿­ °Ë»ç ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é ¼¼°èÀÇ µ­±â¿­ °Ë»ç ½ÃÀå ±Ô¸ð´Â 2025-2030³â°£ ¿¬Æò±Õ 5.22%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 8¾ï 2,261¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

µµ½ÃÈ­, ±âÈÄ º¯È­, ÇØ¿Ü¿©Çà Áõ°¡ µîÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ µ­±â¿­ÀÇ ÁÖ¿ä ¸Å°³¸ð±âÀÎ Aedes aegyptiÀÇ ¼­½ÄÁö°¡ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2023³â¿¡´Â Àεµ¿¡¼­ 30¸¸ ¸í¿¡ °¡±î¿î µ­±â¿­ ȯÀÚ°¡ º¸°íµÇ¾î ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ µ­±â¿­ À¯ÇàÀÌ È®´ëµÇ°í ÀÖÀ½À» ¾Ë ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßº´·ü Áõ°¡´Â Á¶±â ¹ß°ß°ú ½Å¼ÓÇÑ Ä¡·á¸¦ °¡´ÉÇÏ°Ô ÇÏ´Â È¿À²ÀûÀÎ Áø´Ü ÅøÀÇ °³¹ß ¹× ¹èÆ÷°¡ ÇÊ¿äÇϸç, À̸¦ ÅëÇØ Áúº´°ú °ü·ÃµÈ ÀÌȯÀ²°ú »ç¸Á·üÀ» ³·Ãâ ¼ö ÀÖ½À´Ï´Ù.

Áø´Ü ±â¼úÀÇ Çõ½ÅÀ¸·Î µ­±â¿­ °ËÃâÀÇ Á¤È®µµ¿Í ¼Óµµ°¡ Å©°Ô Çâ»óµÇ¾ú½À´Ï´Ù. È¿¼Ò °áÇÕ ¸é¿ª ÈíÂø ºÐ¼®¹ý(ELISA), ¿ªÀü»ç ÁßÇÕÈ¿¼Ò ¿¬¼â¹ÝÀÀ(RT-PCR), ½Å¼Ó Ç׿ø °Ë»ç µî ÷´Ü ¹æ¹ýÀÇ µµÀÔÀº ÀÌ ºÐ¾ß¿¡ Çõ¸íÀ» ÀÏÀ¸Ä×½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀº ¹Î°¨µµ¿Í ƯÀ̵µ°¡ ³ô¾Æ ÀÇ·áÁøÀÌ µ­±â¿­ °¨¿°À» ½Å¼ÓÇÏ°Ô Áø´ÜÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÇöÀå Áø´Ü ÀåºñÀÇ °³¹ß·Î ¿ø°ÝÁö³ª ÀÚ¿øÀÌ ºÎÁ·ÇÑ È¯°æ¿¡¼­ ¸Å¿ì Áß¿äÇÑ ÇöÀå Áø´ÜÀÌ ¿ëÀÌÇØÁ³½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±ÇÒ »Ó¸¸ ¾Æ´Ï¶ó °¨¿° È®»êÀ» ¾ïÁ¦ÇÏ´Â µ¥¿¡µµ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

Á¤ºÎ ¹× ±¹Á¦ÀûÀÎ ³ë·ÂÀº µ­±â¿­ °Ë»ç ½ÃÀåÀ» °­È­ÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖÀ¸¸ç, 2024³â 8¿ù ¹Ì±¹ ±¹Á¦°³¹ßó(USAID)´Â Áö¿ª ¹ßº´ ´ëÀÀÀ» °­È­Çϱâ À§ÇØ 2¸¸ ´Þ·¯ »ó´çÀÇ µ­±â¿­ ¹× ±âŸ ¾Æ¸£º¸¹ÙÀÌ·¯½º °Ë»ç ŰƮ¸¦ Ä«¸®ºêÇØ °øÁߺ¸°Ç±¹(CARPHA)¿¡ ±âÁõÇß½À´Ï´Ù. º¸°Ç±¹(CARPHA)¿¡ 2¸¸ ´Þ·¯ »ó´çÀÇ µ­±â¿­ ¹ÙÀÌ·¯½º ¹× ±âŸ ¾Æ¸£º¸¹ÙÀÌ·¯½º °Ë»ç ŰƮ¸¦ ±âÁõÇß½À´Ï´Ù. ÀÌ·¯ÇÑ ±¸»óÀº Ãë¾àÇÑ Áö¿ªÀÇ Áø´Ü ¿ª·® °­È­¿¡ ´ëÇÑ ¿ì¸®ÀÇ ¾à¼ÓÀ» °­Á¶ÇÏ´Â °ÍÀÔ´Ï´Ù. ¶ÇÇÑ ¹Ì±¹ ½ÄǰÀǾ౹(FDA)°ú °°Àº ±ÔÁ¦±â°üÀº 2024³â 12¿ù Ưº° 510(k) ½ÂÀÎÀ» ¹ÞÀº ¹ÙÀÌ¿À¸Þ«ê«å?ÀÇ BIOFIRE FILMARRAY ¿­´ë¿­ ÆÐ³Î°ú °°Àº Çõ½ÅÀûÀÎ Áø´Ü ¼Ö·ç¼Ç¿¡ ´ëÇÑ ½ÂÀÎÀ» ½Å¼ÓÈ÷ ó¸®Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Çù·ÂÀû ³ë·ÂÀº ÷´Ü Áø´Ü ÅøÀÇ Àü ¼¼°è º¸±Þ°ú Ȱ¿ëÀ» ÃËÁøÇÒ ¼ö ÀÖ½À´Ï´Ù.

µ­±â¿­°ú ±× ¿µÇâ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ Áø´Ü °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. °øÁߺ¸°Ç Ä·ÆäÀΰú ±³À° ÇÁ·Î±×·¥Àº Áö¿ª»çȸ¿¡ µ­±â¿­ÀÇ Áõ»ó, °¨¿° ¹× ¿¹¹æ¿¡ ´ëÇÑ Á¤º¸¸¦ Á¦°øÇÏ´Â µ¥ µµ¿òÀ» ÁÖ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀνÄÀº »ç¶÷µéÀÌ Àû½Ã¿¡ ÀÇ·á±â°üÀ» ¹æ¹®Çϵµ·Ï À¯µµÇÏ¿© È¿À²ÀûÀÎ Áø´Ü ¼­ºñ½º°¡ ÇÊ¿äÇÏ°Ô µË´Ï´Ù. ¶ÇÇÑ Á¤º¸¸¦ ¾òÀº Áö¿ª»çȸ´Â ¸Å°³¸ð±â ÅðÄ¡ Ȱµ¿¿¡ ´õ ½±°Ô Âü¿©ÇÏ°Ô µÇ¾î °£Á¢ÀûÀ¸·Î Áúº´ °ü¸®¿¡ ±â¿©ÇÏ°Ô µË´Ï´Ù. ÀÌó·³ ±³À°°ú °è¸ùÀÇ Á߿伺Àº Áø´Ü¾à ½ÃÀåÀÇ °ßÀÎÂ÷·Î¼­ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.

½Å¼Ó Áø´Ü Å×½ºÆ®(RDT) ŰƮÀÇ °³¹ß°ú º¸±ÞÀ¸·Î µ­±â¿­, ƯÈ÷ À¯Çà Áö¿ª¿¡¼­ µ­±â¿­ °ËÃâ¿¡ ÀÏ´ë º¯ÇõÀÌ ÀϾ½À´Ï´Ù. ÈÄÁöÇʸ§Àº 2023³â 8¿ù, µ¶ÀÚÀûÀÎ Àº ÁõÆø ±â¼úÀ» Ȱ¿ëÇÑ È¹±âÀûÀÎ µ­±â¿­ NS1 Ç׿ø °Ë»ç ŰƮ¸¦ Ãâ½ÃÇÏ¿© Á¶±â Áø´ÜÀ» °¡´ÉÇÏ°Ô ÇÏ´Â µî, ¸î ºÐ ¾È¿¡ ºü¸¥ °á°ú¸¦ Á¦°øÇÏ¿© Áï°¢ÀûÀÎ ÀÓ»óÀû ÆÇ´ÜÀ» ¿ëÀÌÇÏ°Ô ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº Áúº´ÀÇ ½É°¢¼ºÀ» ÁÙÀÌ°í »ç¸Á·üÀ» ³·Ãß´Â µ¥ ¸Å¿ì Áß¿äÇϸç, RDTÀÇ ÆíÀǼº, °æÁ¦¼º ¹× È¿À²¼ºÀº Àü ¼¼°è µ­±â¿­ ÅðÄ¡¿¡ ÇʼöÀûÀÎ ÅøÀÌ µÇ¾î ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.

µ­±â¿­ °Ë»ç ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

  • Á¦Ç°º°·Î´Â ELISA ±â¹Ý °Ë»ç ºÎ¹®ÀÌ 2024³â 44.94%·Î °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇϸç, ³ôÀº ¹Î°¨µµ, ƯÀ̼º, µ­±â¿­ Ç׿ø(NS1)°ú Ç×ü(IgM ¹× IgG)¸¦ ¸ðµÎ °ËÃâÇÒ ¼ö ÀÖ´Â ´É·ÂÀÌ ±× ¿øµ¿·ÂÀÌ µÉ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.
  • ¼­ºñ½º À¯Çüº°·Î´Â Á¤È®Çϰí Á¾ÇÕÀûÀÎ °Ë»ç ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ÀÎÇØ Áß¾Ó ÁýÁᫎ ¼­ºñ½º ºÎ¹®ÀÌ 2024³â 59.93%ÀÇ ¸ÅÃâ Á¡À¯À²·Î ½ÃÀåÀ» ¼±µµÇß½À´Ï´Ù. ÁÖ·Î º´¿ø ¹× Áø´Ü¼¾ÅÍ¿¡ ¼³Ä¡µÈ Áß¾Ó ÁýÁᫎ ½ÇÇè½ÇÀº µ­±â¿­ °¨¿° È®Àο¡ ÇʼöÀûÀÎ ELISA °Ë»ç ¹× RT-PCR °Ë»ç¿Í °°Àº °í±Þ Áø´Ü ±â´ÉÀ» Á¦°øÇÕ´Ï´Ù.
  • ÃÖÁ¾ ¿ëµµº°·Î´Â ÀÓ»ó°Ë»ç ºÎ¹®ÀÌ 2024³â 44.16%ÀÇ ¸ÅÃâ Á¡À¯À²·Î ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù. ¼ºÀåÀÇ ¿øµ¿·ÂÀº ½ÇÇè½Ç ÀÚµ¿È­, °í󸮷® ELISA, RT-PCR Ç÷§Æû¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡·Î ´çÀÏ ´ëÀÀÀÌ °¡´ÉÇØÁ³½À´Ï´Ù´Â Á¡ÀÔ´Ï´Ù.
  • 2024³â¿¡´Â Àεµ, Àεµ³×½Ã¾Æ, ű¹ÀÇ µ­±â¿­ À¯ÇàÀ¸·Î ÀÎÇØ ¾Æ½Ã¾ÆÅÂÆò¾çÀÌ 31.57%ÀÇ Á¡À¯À²·Î ¼¼°è ½ÃÀåÀ» ¼±µµÇß½À´Ï´Ù. ±¹°¡ º¤ÅÍ Á¦¾î ÇÁ·Î±×·¥(¿¹ : ÀεµÀÇ NVBDCP)Àº Áö¿ª ½ÇÇè½Ç¿¡¼­ ELISA ¹× RT-PCR¿¡ ÀÚ±ÝÀ» Áö¿øÇϰí Áö¿ª º¸°Ç ¼¾ÅÍ´Â POC NS1 ½Å¼Ó °Ë»ç¸¦ ¹èÆ÷Çϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå °³¿ä

Á¦3Àå µ­±â¿­ °Ë»ç ½ÃÀåÀÇ º¯¼ö, µ¿Çâ, ¹üÀ§

  • ½ÃÀå ¼¼ºÐÈ­¿Í ¹üÀ§
  • ½ÃÀå °èÅë Àü¸Á
    • ¸ð½ÃÀå Àü¸Á
    • °ü·Ã/º¸Á¶ ½ÃÀå Àü¸Á
  • ½ÃÀå µ¿Çâ°ú Àü¸Á
  • ½ÃÀå ¿ªÇÐ
    • µ­±â¿­ÀÇ ¹ß»ý·ü »ó½Â
    • ±â¼úÀÇ Áøº¸
    • Á¤ºÎ¿Í ±¹Á¦ÀûÀÎ ±¸»ó
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
    • Áø´Ü °Ë»çÀÇ °íºñ¿ë
    • ÇコÄɾî ÀÎÇÁ¶ó¿¡ ´ëÇÑ Á¦ÇÑµÈ ¾×¼¼½º
    • Porter's Five Forces ºÐ¼®
    • PESTEL ºÐ¼®

Á¦4Àå µ­±â¿­ °Ë»ç ½ÃÀå : Á¦Ç°º°, ÃßÁ¤¡¤µ¿Ç⠺м®

  • µ­±â¿­ °Ë»ç ½ÃÀå : Á¦Ç° º¯µ¿ ºÐ¼®
  • Á¦Ç°º°
  • ELISA ±â¹Ý °Ë»ç
  • µ­±â¿­ IgG/IgM °ËÃâ ŰƮ
  • RT-PCR °Ë»ç
  • ½Å¼Ó Áø´Ü °Ë»ç(RDT)
  • NS1 Ç׿ø °ËÃâ ŰƮ
  • Ãø¹æÀ¯µ¿ ¸é¿ªÃøÁ¤

Á¦5Àå µ­±â¿­ °Ë»ç ½ÃÀå : ¼­ºñ½º À¯Çüº°, ÃßÁ¤¡¤µ¿Ç⠺м®

  • µ­±â¿­ °Ë»ç ½ÃÀå : ¼­ºñ½º À¯Çü º¯µ¿ ºÐ¼®
  • ¼­ºñ½º À¯Çüº°
  • ÁýÁßÇü ¼­ºñ½º
  • POC ¼­ºñ½º

Á¦6Àå µ­±â¿­ °Ë»ç ½ÃÀå : ÃÖÁ¾ ¿ëµµº°, ÃßÁ¤¡¤µ¿Ç⠺м®

  • µ­±â¿­ °Ë»ç ½ÃÀå : ÃÖÁ¾ ¿ëµµ º¯µ¿ ºÐ¼®
  • ÃÖÁ¾ ¿ëµµº°
  • ÀÓ»ó °Ë»ç½Ç
  • º´¿ø/Ŭ¸®´Ð
  • ÀçÅà ÇコÄɾî

Á¦7Àå µ­±â¿­ °Ë»ç ½ÃÀå : Áö¿ªº°, ÃßÁ¤¡¤µ¿Ç⠺м®

  • µ­±â¿­ °Ë»ç ½ÃÀå Á¡À¯À²(Áö¿ªº°), 2024³â°ú 2030³â
  • Áö¿ªº° ½ÃÀå Á¡À¯À² ºÐ¼®, 2024³â°ú 2030³â
  • Áö¿ªº° ½ÃÀå ´ë½Ãº¸µå
  • ¼¼°è Áö¿ª ½ÃÀå ½º³À¼ô
  • ½ÃÀå ±Ô¸ð, ¿¹Ãø µ¿Ç⠺м®, 2018-2030³â
  • ºÏ¹Ì
    • ºÏ¹ÌÀÇ µ­±â¿­ °Ë»ç ½ÃÀå, 2018-2030³â
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • À¯·´ÀÇ µ­±â¿­ °Ë»ç ½ÃÀå, 2018-2030³â
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • µ§¸¶Å©
    • ½º¿þµ§
    • ³ë¸£¿þÀÌ
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ µ­±â¿­ °Ë»ç ½ÃÀå, 2018-2030³â
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • ű¹
    • Çѱ¹
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ µ­±â¿­ °Ë»ç ½ÃÀå, 2018-2030³â
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ µ­±â¿­ °Ë»ç ½ÃÀå, 2018-2030³â
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • Äí¿þÀÌÆ®

Á¦8Àå °æÀï ±¸µµ

  • ÁÖ¿ä ½ÃÀå Âü¿© ±â¾÷¿¡ ÀÇÇÑ ÃÖ±Ù µ¿Çâ°ú ¿µÇ⠺м®
  • ±â¾÷ ºÐ·ù
  • Àü·« ÁöµµÁ¦ÀÛ
  • ±â¾÷ ½ÃÀå Á¡À¯À² ºÐ¼®, 2024³â
  • ±â¾÷ °³¿ä
    • Thermo Fisher Scientific Inc.
    • Abbott
    • F. Hoffmann-La Roche Ltd.
    • InBios International, Inc.
    • NovaTec Immundiagnostica GmbH
    • Abnova Corporation
    • PerkinElmer Inc.(Euroimmun AG)
    • Certest BIoTec
    • DiaSorin SpA
    • Quest Diagnostics Incorporated
KSA 25.06.25

Dengue Testing Market Growth & Trends:

The global dengue testing market size is expected to reach USD 822.61 million by 2030, registering a CAGR of 5.22% from 2025 to 2030, according to a new report by Grand View Research, Inc. Factors such as urbanization, climate change, and increased international travel have expanded the habitats of Aedes mosquitoes, the primary vectors for dengue transmission. For instance, in 2023, India reported nearly 300,000 dengue cases, highlighting the disease's growing prevalence in Asia-Pacific region. This escalating incidence necessitates the development and deployment of efficient diagnostic tools to enable early detection and prompt treatment, thereby reducing morbidity and mortality associated with the disease.

Innovations in diagnostic technologies have significantly improved the accuracy and speed of dengue detection. The introduction of advanced methods such as enzyme-linked immunosorbent assays (ELISA), reverse transcription-polymerase chain reaction (RT-PCR), and rapid antigen tests has revolutionized the field. These technologies offer high sensitivity and specificity, enabling healthcare providers to diagnose dengue infections promptly. Moreover, the development of point-of-care testing devices facilitates on-site diagnostics, crucial in remote or resource-limited settings. Such advancements not only enhance patient outcomes but also contribute to controlling the spread of the disease.

Governmental and international efforts play a pivotal role in bolstering the dengue testing market. In August 2024, the United States Agency for International Development (USAID) donated dengue and other arbovirus test kits, valued at USD 20,000, to the Caribbean Public Health Agency (CARPHA) to enhance regional outbreak response. Such initiatives underscore the commitment to strengthening diagnostic capacities in vulnerable regions. Additionally, regulatory bodies like the U.S. Food and Drug Administration (FDA) have expedited the approval of innovative diagnostic solutions, such as bioMerieux's BIOFIRE FILMARRAY Tropical Fever Panel, which received Special 510(k) clearance in December 2024. These concerted efforts facilitate the availability and adoption of advanced diagnostic tools globally.

Heightened awareness about dengue fever and its implications has led to increased demand for diagnostic testing. Public health campaigns and educational programs have been instrumental in informing communities about the symptoms, transmission, and prevention of dengue. This awareness encourages individuals to seek timely medical attention, thereby necessitating efficient diagnostic services. Furthermore, informed communities are more likely to participate in vector control initiatives, indirectly contributing to disease management. The emphasis on education and awareness thus plays a critical role in driving the diagnostics market.

The development and availability of rapid diagnostic test (RDT) kits have transformed dengue detection, especially in endemic regions. These kits offer quick results, often within minutes, facilitating immediate clinical decisions. In August 2023, Fujifilm launched its revolutionary Dengue NS1Ag Test Kit, utilizing proprietary silver amplification technology to enable early diagnosis. Such innovations are crucial in mitigating disease severity and reducing mortality rates. The convenience, affordability, and efficiency of RDTs make them indispensable tools in the global fight against dengue, thereby propelling market growth.

Dengue Testing Market Report Highlights:

  • Based on product, the ELISA-based tests segment accounted for the largest market share of 44.94% in 2024, driven by their high sensitivity, specificity, and ability to detect both dengue antigens (NS1) and antibodies (IgM and IgG).
  • Based on service type, the centralized service segment led the market with a 59.93% revenue share in 2024, driven by the increasing demand for accurate and comprehensive testing solutions. Centralized laboratories, primarily located in hospitals and diagnostic centers, offer advanced diagnostic capabilities, including ELISA and RT-PCR tests, which are essential for confirming dengue infections
  • Based on end use, the clinical labs segment dominated the market with a revenue share of 44.16% in 2024. Growth is driven by increased investments in laboratory automation, high?throughput ELISA, and RT?PCR platforms, enabling same?day turnaround.
  • In 2024, Asia Pacific led the global market with a share of 31.57%, owing to endemic dengue transmission in India, Indonesia, and Thailand. National vector control programs (e.g., India's NVBDCP) fund ELISA and RT?PCR in regional labs, while community health centers deploy POC NS1 rapid tests.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Service Type
    • 1.2.3. End Use
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Service Type outlook
    • 2.2.3. End use outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Dengue Testing Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Trends and Outlook
  • 3.4. Market Dynamics
    • 3.4.1. Rising Incidence of Dengue
    • 3.4.2. Technological Advancements
    • 3.4.3. Government and International Initiatives
  • 3.5. Market Restraint Analysis
    • 3.5.1. High Cost of Diagnostic Tests
    • 3.5.2. Limited Access to Healthcare Infrastructure
    • 3.5.3. Porter's Five Forces Analysis
    • 3.5.4. PESTEL Analysis

Chapter 4. Dengue Testing Market: Product Estimates & Trend Analysis

  • 4.1. Dengue Testing Market: Product Movement Analysis
  • 4.2. Dengue Testing Market Estimates and Forecast, by Product
  • 4.3. ELISA-based Tests
    • 4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4. Dengue IgG/IgM Detection Kits
    • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. RT-PCR Tests
    • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Rapid Diagnostic Tests (RDTs)
    • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. NS1 Antigen Detection Kits
    • 4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8. Lateral Flow Immunoassay
    • 4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Dengue Testing Market: Service Type Estimates & Trend Analysis

  • 5.1. Dengue Testing Market: Service Type Movement Analysis
  • 5.2. Dengue Testing Market Estimates and Forecast, by Service Type
  • 5.3. Centralized Service
    • 5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4. POC Service
    • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Dengue Testing Market: End Use Estimates & Trend Analysis

  • 6.1. Dengue Testing Market: Distribution Movement Analysis
  • 6.2. Dengue Testing Market Estimates and Forecast, by End Use
  • 6.3. Clinical Labs
    • 6.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4. Hospitals /Clinics
    • 6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Home Healthcare
    • 6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Dengue Testing Market: Regional Estimates & Trend Analysis

  • 7.1. Dengue Testing Market Share By Region, 2024 & 2030
  • 7.2. Regional Market Share Analysis, 2024 & 2030
  • 7.3. Regional Market Dashboard
  • 7.4. Global Regional Market Snapshot
  • 7.5. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.6. North America
    • 7.6.1. North America Dengue Testing Market, 2018 - 2030 (USD Million)
    • 7.6.2. U.S.
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. U.S. Dengue Testing Market, 2018 - 2030 (USD Million)
    • 7.6.3. Canada
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Canada Dengue Testing Market, 2018 - 2030 (USD Million)
    • 7.6.4. Mexico
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Competitive Scenario
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Mexico Dengue Testing Market, 2018 - 2030 (USD Million)
  • 7.7. Europe
    • 7.7.1. Europe Dengue Testing Market, 2018 - 2030 (USD Million)
    • 7.7.2. UK
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Competitive Scenario
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. UK Dengue Testing Market, 2018 - 2030 (USD Million)
    • 7.7.3. Germany
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Competitive Scenario
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Germany Dengue Testing Market, 2018 - 2030 (USD Million)
    • 7.7.4. France
      • 7.7.4.1. Key Country Dynamics
      • 7.7.4.2. Competitive Scenario
      • 7.7.4.3. Regulatory Framework
      • 7.7.4.4. France Dengue Testing Market, 2018 - 2030 (USD Million)
    • 7.7.5. Italy
      • 7.7.5.1. Key Country Dynamics
      • 7.7.5.2. Competitive Scenario
      • 7.7.5.3. Regulatory Framework
      • 7.7.5.4. Italy Dengue Testing Market, 2018 - 2030 (USD Million)
    • 7.7.6. Spain
      • 7.7.6.1. Key Country Dynamics
      • 7.7.6.2. Competitive Scenario
      • 7.7.6.3. Regulatory Framework
      • 7.7.6.4. Spain Dengue Testing Market, 2018 - 2030 (USD Million)
    • 7.7.7. Denmark
      • 7.7.7.1. Key Country Dynamics
      • 7.7.7.2. Competitive Scenario
      • 7.7.7.3. Regulatory Framework
      • 7.7.7.4. Denmark Dengue Testing Market, 2018 - 2030 (USD Million)
    • 7.7.8. Sweden
      • 7.7.8.1. Key Country Dynamics
      • 7.7.8.2. Competitive Scenario
      • 7.7.8.3. Regulatory Framework
      • 7.7.8.4. Sweden Dengue Testing Market, 2018 - 2030 (USD Million)
    • 7.7.9. Norway
      • 7.7.9.1. Key Country Dynamics
      • 7.7.9.2. Competitive Scenario
      • 7.7.9.3. Regulatory Framework
      • 7.7.9.4. Norway Dengue Testing Market, 2018 - 2030 (USD Million)
  • 7.8. Asia Pacific
    • 7.8.1. Asia Pacific Dengue Testing Market, 2018 - 2030 (USD Million)
    • 7.8.2. Japan
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Competitive Scenario
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Japan Dengue Testing Market, 2018 - 2030 (USD Million)
    • 7.8.3. China
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Competitive Scenario
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. China Dengue Testing Market, 2018 - 2030 (USD Million)
    • 7.8.4. India
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Competitive Scenario
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. India Dengue Testing Market, 2018 - 2030 (USD Million)
    • 7.8.5. Australia
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Competitive Scenario
      • 7.8.5.3. Regulatory Framework
      • 7.8.5.4. Australia Dengue Testing Market, 2018 - 2030 (USD Million)
    • 7.8.6. Thailand
      • 7.8.6.1. Key Country Dynamics
      • 7.8.6.2. Competitive Scenario
      • 7.8.6.3. Regulatory Framework
      • 7.8.6.4. Thailand Dengue Testing Market, 2018 - 2030 (USD Million)
    • 7.8.7. South Korea
      • 7.8.7.1. Key Country Dynamics
      • 7.8.7.2. Competitive Scenario
      • 7.8.7.3. Regulatory Framework
      • 7.8.7.4. South Korea Dengue Testing Market, 2018 - 2030 (USD Million)
  • 7.9. Latin America
    • 7.9.1. Latin America Dengue Testing Market, 2018 - 2030 (USD Million)
    • 7.9.2. Brazil
      • 7.9.2.1. Key Country Dynamics
      • 7.9.2.2. Competitive Scenario
      • 7.9.2.3. Regulatory Framework
      • 7.9.2.4. Brazil Dengue Testing Market, 2018 - 2030 (USD Million)
    • 7.9.3. Argentina
      • 7.9.3.1. Key Country Dynamics
      • 7.9.3.2. Competitive Scenario
      • 7.9.3.3. Regulatory Framework
      • 7.9.3.4. Argentina Dengue Testing Market, 2018 - 2030 (USD Million)
  • 7.10. MEA
    • 7.10.1. MEA Dengue Testing Market, 2018 - 2030 (USD Million)
    • 7.10.2. South Africa
      • 7.10.2.1. Key Country Dynamics
      • 7.10.2.2. Competitive Scenario
      • 7.10.2.3. Regulatory Framework
      • 7.10.2.4. South Africa Dengue Testing Market, 2018 - 2030 (USD Million)
    • 7.10.3. Saudi Arabia
      • 7.10.3.1. Key Country Dynamics
      • 7.10.3.2. Competitive Scenario
      • 7.10.3.3. Regulatory Framework
      • 7.10.3.4. Saudi Arabia Dengue Testing Market, 2018 - 2030 (USD Million)
    • 7.10.4. UAE
      • 7.10.4.1. Key Country Dynamics
      • 7.10.4.2. Competitive Scenario
      • 7.10.4.3. Regulatory Framework
      • 7.10.4.4. UAE Dengue Testing Market, 2018 - 2030 (USD Million)
    • 7.10.5. Kuwait
      • 7.10.5.1. Key Country Dynamics
      • 7.10.5.2. Competitive Scenario
      • 7.10.5.3. Regulatory Framework
      • 7.10.5.4. Kuwait Dengue Testing Market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Strategy Mapping
  • 8.4. Company Market Share Analysis, 2024
  • 8.5. Company Profiles
    • 8.5.1. Thermo Fisher Scientific Inc.
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Abbott
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. F. Hoffmann-La Roche Ltd.
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. InBios International, Inc.
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. NovaTec Immundiagnostica GmbH
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Abnova Corporation
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. PerkinElmer Inc. (Euroimmun AG)
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Certest Biotec
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. DiaSorin S.p.A.
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Quest Diagnostics Incorporated
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦